Journal
ANNALS OF HEMATOLOGY
Volume 102, Issue 8, Pages 2001-2013Publisher
SPRINGER
DOI: 10.1007/s00277-023-05286-3
Keywords
T cell acute lymphoblastic leukemia; lymphoma; Targeted therapy; Immunotherapy
Categories
Ask authors/readers for more resources
T cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL) is an aggressive malignancy of progenitor T cells. Despite improvements in survival, relapsed and refractory T-ALL remains a significant challenge. Next-generation sequencing has identified new therapeutic targets and immunotherapies, such as NOTCH1 inhibitors and CAR T cell therapy, for T-ALL/LBL. This review discusses the progress and future directions of these targeted therapies and immunotherapies.
T cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL) is an aggressive malignancy of progenitor T cells. Despite significant improvements in survival of T-ALL/LBL over the past decades, treatment of relapsed and refractory T-ALL (R/R T-ALL/LBL) remains extremely challenging. The prognosis of R/R T-ALL/LBL patients who are intolerant to intensive chemotherapy remains poor. Therefore, innovative approaches are needed to further improve the survival of R/R T-ALL/LBL patients. With the widespread use of next-generation sequencing in T-ALL/LBL, a range of new therapeutic targets such as NOTCH1 inhibitors, JAK-STAT inhibitors, and tyrosine kinase inhibitors have been identified. These findings led to pre-clinical studies and clinical trials of molecular targeted therapy in T-ALL/LBL. Furthermore, immunotherapies such as CD7 CAR T cell therapy and CD5 CAR T cell therapy have shown profound response rate in R/R T-ALL/LBL. Here, we review the progress of targeted therapies and immunotherapies for T-ALL/LBL, and look at the future directions and challenges for the further use of these therapies in T-ALL/LBL.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available